OncoMatch/Clinical Trials/NCT02429687
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Is NCT02429687 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for ovarian germ cell cancer.
Treatment: Paclitaxel · Carboplatin · Bleomycin · Etoposide · Cisplatin — Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IIA, IIB, IIC, IIIA, IIIB, IIIC, IVA, IVB
Demographics
Prior therapy
Must have received: surgery — diagnosis, staging, or cytoreduction
Has undergone initial surgery (for diagnosis, staging, or cytoreduction) within the past 8 weeks.
Lab requirements
Blood counts
wbc≥4×10(9)/l, neu≥2×10(9)/l, plt≥80×10(9)/l
Kidney function
bun, cr≤ normal
Liver function
serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02429687 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery.
What disease stage is eligible?
Stage IIA or IIB or IIC or IIIA or IIIB or IIIC or IVA or IVB is required.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 14 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages